http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CO-5690584-A2

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-435
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D241-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-82
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D237-08
filingDate 2006-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0df7171bbca573d8e7158b4760c1d55d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08aa9a0ba83c3b64e64d5fb66a7eaaad
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2e6de93399b16fca8512d7b71b40edec
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8e0d6432f5b9600d394f4b154c2d89fe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5c174489779f24430204988931d2f8ab
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4adcd31e3b2ff98f8bcc39b8eb11755a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7d7de64bcb7da7a397ca2598d7c562db
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5df9d7e996793a85d4a746fdaa693d97
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fcdd1f1b419b833bf05999d8f6dc08a2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_500c119a1159d40f3e2bb161feba719c
publicationDate 2006-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CO-5690584-A2
titleOfInvention PHENYLATE DERIVATIVES AS PPAR AGONISTS
abstract 1.- Compounds of formula and enantiomers and pharmaceutically acceptable salts and esters thereof, where X1 is O, S, CH2 R1 is hydrogen or C1-7-alkyl; R2 is hydrogen or C1-7-alkyl, or, if X1 is CH2, R2 is hydrogen, C1-7-alkyl or C1-7-alkoxy; R3 is hydrogen or C1-7-alkyl; R4 and R8 independently of each other are hydrogen, C1-7-alkyl, C3-7- cycloalkyl, halogen, C1-7-alkoxy-C1-7-alkyl, C2-7-alkenyl, C2-7-alkynyl, fluoro-C1-7 -alkyl, or cyano-C1-7-alkyl or cyano; R5, R6 and R7 independently of each other are hydrogen, C1-7-alkyl, C3-7 -cycloalkyl, halogen, C1-7-C1-7-alkoxy-alkyl, C2-7-alkenyl, C2-7-alkynyl, fluoro- C1-7-alkyl, - cyano-C1-7-alkyl or cyano; and one of R5, R6 and R7, is, where X2 is S, O, NR9, (CH2) pNR9CO, or (CH2) pCONR9, R9 is hydrogen , C1-7-alkyl, C3-7-cycloalkyl, fluoro-C1-7-alkyl, hydroxy-C2-7-alkyl, or C1-7-alkoxy-C2-7-alkyl; Y1, Y2, Y3 and Y4 are N or C-R12, and 1 or 2 of Y1, Y2, Y3 and Y4 are N and the others are C-R1 2; R10 is C1-7-alkyl, C3-7-cycloalkyl, fluoro-C1-7-alkyl, or C1-7-alkoxy-C1-7-alkyl; R11 is hydrogen, C1-7-alkyl, C1-7 -alkoxy-C1-7-alkyl; R12 independently of each other in each case is selected from hydrogen, C1-7-alkyl, C3-7-cycloalkyl, fluoro-C1-7-alkyl, C1-7-alkoxy-C1 -7-alkyl, hydroxy-C1-7-alkyl, C1-7-alkylthio-C1-7-alkyl, carboxy -C1-7-alkoxy -C1-7-alkyl, carboxy, carboxy-C1-7-alkyl, mono - or di-C1-7-alkyl-amino-C1-7-alkyl, C1-7-alkanoyl-C1-7-alkyl, C2-7-alkenyl, and C2-7-alkynyl; ...
priorityDate 2003-11-05-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458392451
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458397365
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID454973655

Total number of triples: 33.